A look at the biologics, gene therapies, and vaccines most likely to reshape care —and manufacturing—in the year ahead.

The suit was filed by the U.S. Equal Employment Opportunity Commission on behalf of a hospital employee who was fired in 2021.

As the Trump administration shakes up recommendations for childhood vaccines, a growing number of states are moving quickly to ensure vaccines remain free and health care workers are protected from ...

Comprehensive VAX-31 Adult Phase 3 Clinical Program, Finalized in Consultation and Alignment with FDA, Advances with Three Phase 3 Studies Underway to Support Planned BLA Submission Topline Safety, To ...

Comprehensive VAX-31 Adult Phase 3 Clinical Program, Finalized in Consultation and Alignment with FDA, Advances with Three Phase 3 Studies Underway to Support Planned BLA Submission ...

The American Medical Association (AMA) and the Vaccine Integrity Project announced that they will independently assess vaccine safety and effectiveness for the 2026-2027 respiratory virus season. This ...

Annual inflation slowed in January, falling more than economists expected, helped by declining prices for gasoline and used vehicles. Cooler price increases overall are positive news for the economy, ...

Inflation slowed in January to its tamest pace since May 2025 as the economy seemingly skirts the full effects of President Trump’s tariffs for now – helped by falling gasoline prices. The Consumer ...

The consumer price index for January accelerated 2.4% from the same time a year ago, down 0.3 percentage point from the prior month and the lowest since May 2025. Excluding food and energy, the core ...

Inflation remained elevated in January as the pace of consumer price growth stayed above the Federal Reserve's target rate as policymakers weigh affordability concerns. The Bureau of Labor Statistics ...

Inflation rose just 0.2% in January from December and fell to 2.4% on an annual basis. Both readings were less than anticipated, in a positive sign for consumers. Broadly, economists surveyed by Dow ...

The Food and Drug Administration has refused to review an application from the biotech company Moderna to approve its mRNA-based flu vaccine. The agency’s decision, which Moderna announced in a press ...